
Daiichi Sankyo (4568) · Pharmaceuticals
Daiichi Sankyo Q2 FY2026 earnings: summary, key numbers & outlook
Results filed 30 Oct 2026 · Quarter ended 30 Sep 2026
Slides (40 pages)Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Daiichi Sankyo is scaling Enhertu and Datroway through new first-line approvals, a Summit Therapeutics combination deal and a single global commercialization unit launching April 2027.
Enhertu became the US market leader in first-line HER2-positive metastatic breast cancer and took the top share in adjuvant early breast cancer. Datroway has treated about 9,800 patients globally, roughly 1.4 times the prior quarter, and leads later-line EGFR-mutated lung cancer in the US. New approvals landed across the US, Europe, Japan and China. Non-oncology units such as American Regent and Lixiana were weaker.
Management is centralizing oncology and specialty commercialization into one unit from April 2027, aiming for 20+ indication launches by 2030 and a global top 5 oncology ranking by 2035. It also plans to test Datroway with Summit's ivonescimab. The tension is dependence on two drugs, with a withdrawn US filing for ifinatamab deruxtecan and a fast-moving small cell lung cancer field.
No call transcript for this quarter, so this summary also draws on: Investing.com ↗, Investing.com ↗.
Slides & documents
Open the slide deck (PDF, 40 pages) ↗
Showing the first 6 of 40 pages.
Results documents
Key numbers
- Revenue (six months)
- JPY1,167.2 billion
- Operating profit (six months) · GAAP
- JPY193.8 billion
- Profit attributable to owners of the Company · GAAP
- JPY151.5 billion
- Diluted earnings per share (six months) · GAAP
- 83.20
- Core operating profit (six months) · non-GAAP
- JPY221.3 billion
- Net cash flows from operating activities (JPY millions) · GAAP
- 50.7B
up 19.7% year on year
up 34.4% year on year
up 15.8% year on year
up from 70.52 a year ago
up 46.9% year on year
from (28,311) a year ago
| Segment or metric | Value | Change |
|---|---|---|
| Oncology Business Unit | JPY422.6 billion | up 54.8% year on year |
| Enhertu global product sales (six months) | 464.5 Bn JPY | up 45.9% year on year |
| Datroway global product sales (six months) | 48.3 Bn JPY | up 207.2% year on year |
| Datroway patients treated since launch | approx. 9,800 | approx. 1.4 times the prior quarter |
| Japan Business Unit | JPY232.7 billion | down 6.9% year on year |
| American Regent Unit | JPY77.9 billion | down 19.5% year on year |
| EU Specialty Business Unit | JPY149.2 billion | up 9.1% year on year |
| ASCA Business Unit | JPY142.5 billion | up 20.9% year on year |
Where each number comes from
- Revenue (six months): “Revenue in the first six months of the year ending March 31, 2027 increased by JPY191.9 billion, or 19.7% year on year, to JPY1,167.2 billion.”
- Operating profit (six months): “Operating profit increased by JPY49.6 billion, or 34.4% year on year, to JPY193.8 billion.”
- Profit attributable to owners of the Company: “Profit attributable to owners of the Company increased by JPY20.7 billion, or 15.8% year on year, to JPY151.5 billion.”
- Diluted earnings per share (six months): “Basic earnings per share (JPY) 70.55 83.22 Diluted earnings per share (JPY) 70.52 83.20”
- Core operating profit (six months): “Core operating profit increased by JPY70.6 billion, or 46.9% year on year, to JPY221.3 billion.”
- Net cash flows from operating activities (JPY millions): “Net cash flows from (used in) operating (28,311) 50,738 activities Cash flows from investing activities Payments into time deposits (24,061) (5,563)”
- Oncology Business Unit: “Revenue from the Unit increased by JPY149.6 billion, or 54.8% year on year, to JPY422.6 billion and the revenue in local currency increased by USD782 million”
- Enhertu global product sales (six months): “Q2 Global Product Sales Result 464.5 Bn JPY 24.5 YoY +146.1 Bn JPY (+45.9%)”
- Datroway global product sales (six months): “Q2 Global Product Sales Result 48.3 Bn JPY 7.0 YoY +32.6 Bn JPY (+207.2%)”
- Datroway patients treated since launch: “Treated approx. 9,800 patients globally since launch, approx. 1.4 times the prior quarter”
- Japan Business Unit: “Revenue from the Unit decreased by JPY17.2 billion, or 6.9% year on year, to JPY232.7 billion due to decreases in sales of Lixiana and others”
- American Regent Unit: “Revenue from American Regent Unit decreased by JPY18.9 billion, or 19.5% year on year, to JPY77.9 billion”
- EU Specialty Business Unit: “on a JPY basis, revenue was JPY149.2 billion, constituting an increase of JPY12.4 billion, or 9.1% year on year”
- ASCA Business Unit: “Revenue from the Unit increased by JPY24.6 billion, or 20.9% year on year, to JPY142.5 billion due to the growth in sales of Enhertu in Brazil”
Copied from the press release ↗ and other documents in the company's results page ↗. A figure is published only if its sentence is in those documents.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Revenue (JPY millions), unchanged from July | fiscal year ending March 31, 2027 | 2,340,000 |
| Basic earnings per share (JPY) | fiscal year ending March 31, 2027 | 137.94 |
| Capital expenditure (JPY billions) | fiscal 2026 | 200.0 |
| Annual dividend per share (JPY) | fiscal 2026 | JPY100 |
Key takeaways
Enhertu leads US first-line HER2+ metastatic breast cancer
Enhertu is now the US market leader in HER2+ first-line metastatic breast cancer and holds the No.1 share in HER2+ adjuvant early breast cancer. First-line approvals in China, Japan and Europe in Aug–Sep 2026 widen the addressable base.
Datroway patient base grew 1.4x in a quarter
About 9,800 patients have been treated globally since launch, and new patient starts grew in all promoted indications. It leads later-line EGFR-mutated NSCLC in the US and is gaining early share in first-line TNBC.
Summit deal pairs Datroway with ivonescimab
Daiichi Sankyo and AstraZeneca will study Datroway with Summit's investigational PD-1/VEGF bispecific ivonescimab across multiple solid tumors, starting with first-line TNBC. Costs are shared and each party keeps rights to its own medicine.
One global commercialization unit starts April 2027
Oncology and specialty commercialization will be centralized into 5 regional businesses and 6 global functions. Management cites 20+ anticipated indication launches by 2030 as the reason.
Ifinatamab deruxtecan US filing withdrawn; Enhertu lung data positive
The US application for I-DXd in previously treated small cell lung cancer was voluntarily withdrawn in September 2026. Separately, DESTINY-Lung04 showed Enhertu beating pembrolizumab plus chemotherapy as first-line treatment for HER2-mutant NSCLC.
Questions
What were Daiichi Sankyo's main product developments this quarter?
Enhertu and Datroway gained first-line approvals across the US, Europe, Japan and China, and Enhertu became US market leader in first-line HER2+ metastatic breast cancer. Datroway treated about 9,800 patients, 1.4 times the prior quarter.
What is the Summit Therapeutics collaboration?
Daiichi Sankyo and AstraZeneca will combine Datroway with Summit's investigational PD-1/VEGF antibody ivonescimab, with trial costs shared and each company keeping rights to its own medicine. The first Phase 3 study is in first-line triple-negative breast cancer.
How is Daiichi Sankyo changing its go-to-market organization?
From April 2027 it will run oncology and specialty commercialization as one global unit, with 5 regional businesses and 6 global functions. The goal is better resource allocation and standardized processes.
What happened with ifinatamab deruxtecan (I-DXd)?
Daiichi Sankyo voluntarily withdrew its US application for previously treated extensive-stage small cell lung cancer in September 2026, after the filing was accepted with priority review in April. The Phase 3 IDeate-Lung02 readout is expected in FY2027.
What upcoming pipeline readouts matter for Datroway?
TROPION-Lung15 is expected in FY2026 H2, and AVANZAR in CY2027 H1. TROPION-Lung07, Lung08, Breast03 and Breast05 are also due in FY2027.





